grant

Development of a unique humanized DR5 activating antibody for treating therapy-resistant cancers

Organization UKRILocation United Kingdom
UKRIUK ResearchGrantActive
Sign up free to applyApply link · pipeline · email alerts
— or —

Get email alerts for similar roles

Weekly digest · no password needed · unsubscribe any time

Description preview

**Targeting DR5: a New Cancer Treatment Strategy**

Cancer cells are like rogue agents in the body that don't follow the usual rules. To tackle these dangerous cells, scientists have found a special pathway involving a protein called **Death Receptor 5 (DR5)** (Alternative names: Tumor necrosis factor receptor superfamily member 10B; TNFRSF10B;…

🔒

Full details available on the Agency plan

Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.

Start 7-day free trial — $29.99/mo →

Agency Plan

7-day free trial

Unlock procurement & grants

Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.

$29.99 / month

  • 🔔Email alerts for new matching tenders
  • 🗂️Track tenders in your pipeline
  • 💰Filter by contract value
  • 📥Export results to CSV
  • 📌Save searches with one click
Start 7-day free trial →

Explore more

📍 More grants in United Kingdom🏷 More UKRI opportunities🏷 More UK Research opportunities🏷 More Grant opportunities🏢 All ukri_grants opportunities
Development of a unique humanized DR5 activating antibody for treating therapy-resistant cancers — UKRI | United Kingdom | Dev Procure